Analyst Downgrades Genomic Health for Lackluster Seasonal Oncotype DX Growth

Nov 02, 2007

NEW YORK (GenomeWeb News) - An analyst for financial services firm Cantor Fitzgerald has downgraded Genomic Health’s stock to a ‘hold’ from a ‘buy’ based on the company’s third-quarter earnings, which were released on Wednesday.

The analyst’s report said growth in Oncotype Dx sales were less than expected within seasonal variation.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Breaking News

The Scan

Closely Intertwined

The New York Times and ProPublica look into the close relationship between a startup and Memorial Sloan Kettering Cancer Center.

Little From Here and There

Yahoo News reports millions of dollars are being transferred from NIH, CDC, and other programs to pay for the housing of detained undocumented immigrant children.

This Week in Science

In Science this week: in vitro generation of human reproductive cells, and more.

All the Arms for Hugging

Researchers gave a handful of octopuses MDMA to find that they too act more social on the drug, Gizmodo reports.

Main menu